DIVA Laboratories, Ltd. and Subsidiaries

Consolidated Financial Statements for the Three Months Ended March 31, 2026 and 2025 and Independent Auditors' Review Report

INDEPENDENT AUDITORS' REVIEW REPORT

The Board of Directors and Shareholders
DIVA Laboratories, Ltd.

Introduction

We have reviewed the accompanying consolidated balance sheets of DIVA Laboratories, Ltd. and its subsidiaries as of March 31, 2026 and 2025, the related consolidated statements of comprehensive income, changes in equity and cash flows for the three months then ended, and the related notes to the consolidated financial statements, including a summary of significant accounting policies (collectively referred to as the "consolidated financial statements"). Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and International Accounting Standard 34 "Interim Financial Reporting" endorsed and issued into effect by the Financial Supervisory Commission of the Republic of China. Our responsibility is to express a conclusion on the consolidated financial statements based on our reviews.

Scope of Review

Except as explained in the Basis for Qualified Conclusion section, we conducted our reviews in accordance with the Standards on Review Engagements of the Republic of China 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity". A review of the consolidated financial statements consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Basis for Qualified Conclusion

As described in Note 12 to the consolidated financial statements, as of March 31, 2026 and 2025, DIVA Laboratories, Ltd. and its subsidiaries accounted for investments using the equity method as of March 31, 2026 and 2025 were NT$2,050 thousand and NT$694 thousand, respectively. The share of profit or loss of associates and joint ventures accounted for using the equity method for the Three Months Ended March 31, 2026 and 2025 amounted to NT$63 thousand and NT$18 thousand, respectively. These amounts were recognized and disclosed based on the investees' financial statements for the same period, which were not reviewed by independent auditors. Information related to the investees as described in Note 31 of the consolidated financial statements was recognized and disclosed based on the investee companies' financial statements for the same periods, which were not reviewed by auditors.

Qualified Conclusion

Based on our review, except for the possible adjustments, if any, as might have been determined to be necessary had the financial statements of the associates accounted for using the equity method, the share of profit or loss of associates recognized under the equity method, and the related information on investee companies as described in the Basis for Qualified Conclusion paragraph been reviewed by independent auditors, nothing has come to our attention that causes us to believe that the accompanying consolidated financial statements do not present fairly, in all material respects, the consolidated financial position of DIVA Laboratories, Ltd. and its subsidiaries as of March 31, 2026 and 2025, and their consolidated financial performance and consolidated cash flows for the Three Months Ended March 31, 2026 and 2025, in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers, and International Accounting Standard 34 "Interim Financial Reporting" as endorsed and issued into effect by the Financial Supervisory Commission of the Republic of China.

The engagement partners on the audits resulting in this independent auditors' report are Chih-Ming Shao and Kuo-Ning Huang.

Deloitte & Touche
Taipei, Taiwan
Republic of China

April 27, 2026

Notice to Readers

The accompanying consolidated financial statements are intended only to present the consolidated financial position, financial performance and cash flows in accordance with accounting principles and practices generally accepted in the Republic of China and not those of any other jurisdictions. The standards, procedures and practices to audit such consolidated financial statements are those generally applied in the Republic of China.

For the convenience of readers, the independent auditors' report and the accompanying consolidated financial statements have been translated into English from the original Chinese version prepared and used in the Republic of China. If there is any conflict between the English version and the original Chinese version or any difference in the interpretation of the two versions, the Chinese-language independent auditors' review report and consolidated financial statements shall prevail.

DIVA LABORATORIES, LTD. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS
(In Thousands of New Taiwan Dollars)

	March 31, 2026		December 31, 2025		March 31, 2025	
ASSETS	**Amount**	**%**	**Amount**	**%**	**Amount**	**%**
CURRENT ASSETS						
Cash and cash equivalents (Note 6)	$ 475,639	34	$ 494,033	36	$ 592,583	44
Financial assets at fair value through profit or loss - current (Notes 4 and 7)	-	-	70	-	-	-
Accounts receivable, net (Notes 9 and 22)	298,292	22	277,728	21	261,259	20
Accounts receivable from related parties (Notes 22 and 28)	2,375	-	7,771	1	9,118	1
Other receivables (Note 9)	9,744	1	11,133	1	6,856	1
Other receivables from related parties (Note 28)	13,344	1	10,441	1	11,254	1
Current tax assets (Note 4)	1,392	-	1,367	-	1,013	-
Inventories (Note 10)	305,012	22	249,816	18	171,975	13
Prepayments (Note 28)	4,717	-	27,271	2	4,323	-
Other current assets (Note 16)	6,651	1	4,735	-	3,608	-
Total current assets	1,117,166	81	1,084,365	80	1,061,989	80
NON-CURRENT ASSETS						
Financial assets at fair value through other comprehensive income - non-current (Note 8)	4,294	-	5,550	1	5,719	1
Investments accounted for using the equity method (Note 12)	2,050	-	2,028	-	-	-
Property, plant and equipment (Note 13)	213,509	16	214,534	16	216,248	16
Right-of-use assets (Note 14)	2,211	-	2,848	-	4,758	-
Intangible assets (Note 15)	822	-	996	-	1,467	-
Deferred tax assets (Note 4)	37,640	3	37,718	3	39,893	3
Net defined benefit assets - non-current	3,957	-	3,816	-	2,252	-
Other non-current assets (Notes 16 and 29)	1,824	-	1,825	-	1,818	-
Total non-current assets	266,307	19	269,315	20	272,155	20
TOTAL	$ 1,383,473	100	$ 1,353,680	100	$ 1,334,144	100
LIABILITIES AND EQUITY						
CURRENT LIABILITIES						
Financial liabilities at fair value through profit or loss - current (Note 7)	$ 1,811	-	$ 1,234	-	$ 2,272	-
Contract liabilities - current (Notes 22 and 28)	8,388	-	8,186	1	6,295	-
Accounts payable (Note 17)	92,106	7	77,378	6	73,194	6
Accounts payable to related parties (Note 28)	139	-	90	-	-	-
Other payables (Note 18)	195,046	14	86,718	6	196,146	15
Other payables to related parties (Note 28)	93,980	7	92,754	7	33,437	3
Current tax liabilities (Note 4)	26,737	2	24,440	2	29,920	2
Provisions - current (Note 19)	13,929	1	13,037	1	10,497	1
Lease liabilities - current (Note 14)	1,974	-	2,593	-	2,554	-
Other current liabilities (Note 18)	12,219	1	17,016	1	12,157	1
Total current liabilities	446,329	32	323,446	24	366,472	28
NON-CURRENT LIABILITIES						
Deferred tax liabilities (Note 4)	791	-	763	-	450	-
Lease liabilities - non-current (Note 14)	284	-	308	-	2,258	-
Credit balance of investments accounted for using the equity method (Note 12)	-	-	-	-	694	-
Total non-current liabilities	1,075	-	1,071	-	3,402	-
Total liabilities	447,404	32	324,517	24	369,874	28
EQUITY (Note 21)						
Ordinary shares	586,682	42	586,682	43	600,906	45
Capital surplus	287,098	21	347,141	26	351,617	26
Retained earnings						
Legal reserve	31,629	2	31,629	2	22,217	2
Special reserve	5,804	1	5,804	-	7,717	1
Unappropriated earnings	31,660	2	64,172	5	32,387	2
Total retained earnings	69,093	5	101,605	7	62,321	5
Other equity	(6,804)	-	(6,265)	-	(4,587)	-
Treasury shares	-	-	-	-	(45,987)	(4)
Total equity	936,069	68	1,029,163	76	964,270	72
TOTAL	$ 1,383,473	100	$ 1,353,680	100	$ 1,334,144	100

The accompanying notes are an integral part of the consolidated financial statements.

DIVA LABORATORIES, LTD. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
For the Three Months Ended March 31, 2026 and 2025
(In Thousands of New Taiwan Dollars, Except Earnings Per Share)

	For the Three Months Ended March 31			
	2026		2025	
	Amount	%	Amount	%
OPERATING REVENUE, NET (Notes 22 and 28)	$ 222,900	100	$ 207,110	100
OPERATING COSTS (Notes 10, 15, 23 and 28)	160,836	72	138,580	67
GROSS PROFIT (LOSS) FROM OPERATIONS	62,064	28	68,530	33
UNREALIZED PROFIT (LOSS) FROM SALES	(41)	-	(610)	-
REALIZED GROSS PROFIT	62,023	28	67,920	33
OPERATING EXPENSES (Notes 9, 15, 20, 23 and 28)				
Selling expenses	6,768	3	7,384	3
General and administrative expenses	12,981	6	12,705	6
Research and development expenses	18,299	8	17,923	9
Expected credit (gain) loss	(3,328)	(1)	37	-
Total operating expenses	34,720	16	38,049	18
PROFIT FROM OPERATIONS	27,303	12	29,871	15
NON-OPERATING INCOME AND EXPENSES				
Interest income (Note 23)	1,230	1	1,213	-
Other income (Notes 23 and 28)	262	-	2,704	1
Finance cost (Note 23)	(179)	-	(25)	-
Share of profit or loss of associates	-	-	(6)	-
Foreign exchange gain, net (Note 30)	4,838	2	3,401	2
Net (loss) gain on financial assets at fair value through profit or loss (Note 7)	(3,531)	(2)	26	-
Loss on disposal of property, plant and equipment, net	-	-	(16)	-
Net loss on financial liabilities at fair value through profit or loss (Note 7)	(2,664)	(1)	(4,725)	(2)
Total non-operating income and expenses	(44)	-	2,572	1
INCOME BEFORE INCOME TAX	27,259	12	32,443	16
INCOME TAX EXPENSE (Note 24)	(2,477)	(1)	(7,555)	(4)
NET INCOME	24,782	11	24,888	12

(Continued)

DIVA LABORATORIES, LTD. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
For the Three Months Ended March 31, 2026 and 2025
(In Thousands of New Taiwan Dollars, Except Earnings Per Share)

	For the Three Months Ended March 31			
	2026		2025	
	Amount	%	Amount	%
OTHER COMPREHENSIVE INCOME (Notes 8, 21 and 27)				
Items that will not be reclassified subsequently to profit or loss:				
Unrealized gain on equity instruments at fair value through other comprehensive income	($ 1,256)	-	$ 687	1
Items that may be reclassified subsequently to profit or loss:				
Exchange differences on translation of the financial statements of foreign operations	654	-	506	-
Share of other comprehensive income of associates accounted for under the equity method	63	-	24	-
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD	$ 24,243	11	$ 26,105	13
NET INCOME ATTRIBUTABLE TO:				
Owners of the Company	$ 24,782	11	$ 24,888	12
TOTAL COMPREHENSIVE INCOME ATTRIBUTABLE TO:				
Owners of the Company	$ 24,243	11	$ 26,105	13
EARNINGS PER SHARE (Note 25)				
Basic	$ 0.42		$ 0.42	
Diluted	$ 0.42		$ 0.42	

(Concluded)

The accompanying notes are an integral part of the consolidated financial statements.

DIVA LABORATORIES, LTD. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
For the Three Months Ended March 31, 2026 and 2025
(In Thousands of New Taiwan Dollars)

	Equity Attributable to Owners of the Company												
	Ordinary Shares (Note 21)		Capital Surplus (Note 21)				Retained Earnings (Note 21)			Other Equity (Notes 8 and 21)			
	Number of Shares (In Thousand)	Amounts	Premium of Shares	Employee Share Options	Share Options	Other	Legal Reserve	Special Reserve	Unappropriated Earnings	Exchange Differences on Translating Foreign Operations	Unrealized (Loss) Gain on Financial Assets at Fair Value Through Other Comprehensive Income	Treasury Shares (Note 21)	Total Equity
BALANCE ON JANUARY 1, 2025	60,091	$ 600,906	$ 354,184	$ 6,767	$ 9,654	$ 11,726	$ 22,217	$ 7,717	$ 94,122	$ 1,164	($ 6,968)	($ 45,987)	$ 1,055,502
Appropriation of 2024 earnings													
Cash dividends - NT$1.47648427 per share	-	-	-	-	-	-	-	-	(86,623)	-	-	-	(86,623)
Cash dividends distributed from capital surplus - NT$0.52351573 per share	-	-	(30,714)	-	-	-	-	-	-	-	-	-	(30,714)
Net profit for the three months ended March 31, 2025	-	-	-	-	-	-	-	-	24,888	-	-	-	24,888
Other comprehensive income (loss) for the three months ended March 31, 2025, net of income tax	-	-	-	-	-	-	-	-	-	530	687	-	1,217
BALANCE ON MARCH 31, 2025	60,091	$ 600,906	$ 323,470	$ 6,767	$ 9,654	$ 11,726	$ 22,217	$ 7,717	$ 32,387	$ 1,694	($ 6,281)	($ 45,987)	$ 964,270
BALANCE ON JANUARY 1, 2026	58,668	$ 586,682	$ 318,994	$ 6,767	$ 9,654	$ 11,726	$ 31,629	$ 5,804	$ 64,172	$ 185	($ 6,450)	$ -	$ 1,029,163
Appropriation of 2025 earnings													
Cash dividends - NT$0.97657128 per share	-	-	-	-	-	-	-	-	(57,294)	-	-	-	(57,294)
Cash dividends distributed from capital surplus - NT$1.02342872 per share	-	-	(60,043)	-	-	-	-	-	-	-	-	-	(60,043)
Net profit for the three months ended March 31, 2026	-	-	-	-	-	-	-	-	24,782	-	-	-	24,782
Other comprehensive income (loss) for the three months ended March 31, 2026, net of income tax	-	-	-	-	-	-	-	-	-	717	(1,256)	-	(539)
BALANCE ON MARCH 31, 2026	58,668	$ 586,682	$ 258,951	$ 6,767	$ 9,654	$ 11,726	$ 31,629	$ 5,804	$ 31,660	$ 902	($ 7,706)	$ -	$ 936,069

The accompanying notes are an integral part of the consolidated financial statements.

DIVA LABORATORIES, LTD. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE THREE MONTHS ENDED MARCH 31, 2026 AND 2025
(In Thousands of New Taiwan Dollars)

	For the Three Months Ended March 31	
	2026	2025
CASH FLOWS FROM OPERATING ACTIVITIES		
Income before income tax	$ 27,259	$ 32,443
Adjustments for:		
Depreciation expense	2,350	2,419
Amortization expense	174	246
Expected credit (gain) loss	(3,328)	37
Loss (gain) on financial assets at fair value through profit or loss, net	3,531	(26)
Loss on financial liabilities at fair value through profit or loss, net	2,664	4,725
Finance cost	179	25
Interest income	(1,230)	(1,213)
Share of profit or loss of associates	-	6
Loss on disposal of property, plant and equipment, net	-	16
Reversal of write-down of inventories	(136)	(4,750)
Unrealized gain on transactions with associates	41	610
Net changes in operating assets and liabilities		
Financial assets mandatorily classified as at fair value through profit or loss	(3,461)	26
Accounts receivable	(16,940)	(9,954)
Accounts receivable from related parties	5,396	2,075
Other receivables	1,424	10,219
Other receivables from related parties	(2,903)	(5,891)
Inventories	(55,056)	(15,802)
Prepayments	22,558	(439)
Other current assets	(1,916)	(2,859)
Net defined benefit assets	(141)	(129)
Financial liabilities held for trading	(2,087)	(4,471)
Contract liabilities	202	(217)
Accounts payable	14,723	2,507
Accounts payable to related parties	49	-
Other payables	(7,269)	(7,591)
Other payables to related parties	998	(830)
Provisions	892	888
Other current liabilities	(4,816)	581
Cash (used in) generated from operations	(16,843)	2,651
Income tax paid	(94)	(84)
Net cash (used in) generated from operating activities	(16,937)	2,567

(Continued)

DIVA LABORATORIES, LTD. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE THREE MONTHS ENDED MARCH 31, 2026 AND 2025
(In Thousands of New Taiwan Dollars)

	For the Three Months Ended March 31	
	2026	2025
CASH FLOWS FROM INVESTING ACTIVITIES		
Payments for property, plant and equipment	($ 2,447)	($ 80)
Decrease (Increase) in refundable deposits	1	(18)
Interest received	1,196	1,226
Net cash (used in) generated from investing activities	(1,250)	1,128
CASH FLOWS FROM FINANCING ACTIVITIES		
Proceeds from short-term borrowings	130,000	-
Repayments of short-term borrowings	(130,000)	-
Repayment of the principal portion of lease liabilities	(643)	(637)
Interest paid	(179)	(25)
Net cash used in financing activities	(822)	(662)
EFFECTS OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS	615	407
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS	(18,394)	3,440
CASH AND CASH EQUIVALENTS, BEGINNING OF THE PERIOD	494,033	589,143
CASH AND CASH EQUIVALENTS, END OF THE PERIOD	$ 475,639	$ 592,583

(Concluded)

The accompanying notes are an integral part of the consolidated financial statements.

1. GENERAL INFORMATION

DIVA Laboratories, Ltd. (the "Company") was incorporated in the Republic of China (ROC) on April 11, 1995 after approval was obtained from the Ministry of Economic Affairs. The Company is mainly engaged in the sale, manufacturing and development of medical equipment and computer related devices.

The Company has obtained approval for public offering by the Financial Supervisory Commission on August 18, 2010. The Company's shares were listed and have been trading on the Emerging Stock Board (ESB) of the Taipei Exchange (TPEx) since October 11, 2010 and its shares have been trading on the Taipei Exchange since May 23, 2013.

The consolidated financial statements of the Company and its subsidiaries (collectively referred to as the "Group") are presented in the Company's functional currency, the New Taiwan dollar.

2. APPROVAL OF CONSOLIDATED FINANCIAL STATEMENTS

The consolidated financial statements were approved by the board of directors on April 27, 2026.

3. APPLICATION OF NEW, AMENDED AND REVISED STANDARDS AND INTERPRETATIONS

a. Initial application of the amendments to the International Financial Reporting Standards (IFRS), International Accounting Standards (IAS), Interpretations of IFRS (IFRIC), and SIC Interpretations (SIC) (collectively, the "IFRS Accounting Standards") endorsed and issued into effect by the Financial Supervisory Commission (FSC)

The initial application of the IFRS Accounting Standards endorsed and issued into effect by the FSC did not have a material impact on the Group's accounting policies and financial performance.

b. The IFRS Accounting Standards in issue but not yet endorsed and issued into effect by the FSC

New, Amended and Revised Standards and Interpretations	Effective Date Announced by IASB (Note)
Amendments to IFRS 10 and IAS 28 "Sale or Contribution of Assets between an Investor and its Associate or Joint Venture"	To be determined by IASB
IFRS 18 "Presentation and Disclosure in Financial Statements"	January 1, 2027 (Note 2)
IFRS 19 "Subsidiaries without Public Accountability: Disclosures"	January 1, 2027
Amendments to IAS 21 "Translation to a Hyperinflationary Presentation Currency"	January 1, 2027

Note 1: Unless stated otherwise, the above IFRS Accounting Standards are effective for annual reporting periods beginning on or after their respective effective dates.

Note 2: On September 25, 2025, the FSC announced that IFRS 18 will take effect starting from January 1, 2028. Domestic entities could elect to apply IFRS 18 for an earlier period after the endorsement of IFRS 18 by the FSC.

IFRS 18 “Presentation and Disclosure in Financial Statements”

IFRS 18 will supersede IAS 1 “Presentation of Financial Statements”. The main changes comprise:

- To classify items of income and expenses presented in the statement of profit or loss into the operating, investing, financing, income taxes and discontinued operations categories, the Group shall assess whether it has specified main business activities of investing in particular types of assets and providing financing to customers.

- The statement of profit or loss shall present totals and subtotals for operating profit or loss, profit or loss before financing and income taxes and profit or loss.

- Provides guidance to enhance the requirements of aggregation and disaggregation: The Group shall identify the assets, liabilities, equity, income, expenses and cash flows that arise from individual transactions or other events and shall classify and aggregate them into groups based on shared characteristics, so as to result in the presentation in the primary financial statements of line items that have at least one similar characteristic. The Group shall disaggregate items with dissimilar characteristics in the primary financial statements and in the notes. The Group labels items as “other” only if it cannot find a more informative label.

- Disclosures on Management-defined Performance Measures (MPMs): When in public communications outside financial statements and communicating to users of financial statements management’s view of an aspect of the financial performance of the Group as a whole, the Group shall disclose related information about its MPMs in a single note to the financial statements, including the description of such measures, calculations, reconciliations to the subtotal or total specified by IFRS Accounting Standards and the income tax and non-controlling interests effects of related reconciliation items.

In addition, the following consequential amendments have been made to IAS 7 “Statement of Cash Flows”:

- The Group shall use operating profit or loss as the starting point when presenting cash flows from operating activities under the indirect method.

- Interest and dividends received by the Group shall be classified as investing activities, while interest and dividends paid shall be classified as financing activities. However, if, after assessment, the Group has a specific main operating activity, it shall determine how to classify dividends received, interest received and interest paid in the statement of cash flows by referring to how it classifies dividend income, interest income and interest expense in the statement of profit or loss. The total of each of these cash flows shall be classified in a single category in the statement of cash flows.

Except for the above impact, as of the date the consolidated financial statements were authorized for issue, the Group is continuously assessing the other impacts of the above amended standards and interpretations on the Group’s financial position and financial performance and will disclose the relevant impact when the assessment is completed.

4. SUMMARY OF MATERIAL ACCOUNTING POLICY INFORMATION

a. Statement of compliance

These interim consolidated financial statements have been prepared in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and IAS 34 “Interim Financial Reporting” as endorsed and issued into effect by the FSC. Disclosure information included in these interim consolidated financial statements is less than the disclosure information required in a complete

set of annual consolidated financial statements.

b. Basis of preparation

The consolidated financial statements have been prepared on the historical cost basis except for the financial instruments which are measured at fair value and net defined benefit assets which are measured at the present value of the defined benefit obligation less the fair value of plan assets.

The fair value measurements are grouped into Levels 1 to 3 based on the degree to which the fair value measurement inputs are observable and the significance of the inputs, which are described as follows:

1) Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities;

2) Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e., as prices) or indirectly (i.e., derived from prices)

3) Level 3 inputs are unobservable inputs for the asset or liability.

c. Basis of consolidation

The consolidated financial statements incorporate the financial statements of the Company and the entities controlled by the Company (i.e., its subsidiaries). When necessary, adjustments are made to the consolidated financial statements of subsidiaries to bring their accounting policies into line with those used by the Company. Income and expenses of subsidiaries acquired or disposed of during the period are included in the consolidated statement of comprehensive income from the effective date of acquisition up to the effective date of disposal, as appropriate. All intra-group transactions, balances, income and expenses are eliminated in full upon consolidation.
See Note 11, Tables 2 and 3 for the detailed information of subsidiaries (including the percentage of ownership and main business).

d. Other material accounting policies

Except for the following, please refer to the consolidated financial statements for the year ended December 31, 2025.

1) Retirement benefits
Pension cost for an interim period is calculated on a year-to-date basis by using the actuarially determined pension cost rate at the end of the prior financial year, adjusted for significant market fluctuations since that time and for significant plan amendments, settlements, or other significant one-off events.
2) Income tax expense
Income tax expense represents the sum of the tax currently payable and deferred tax. Interim period income taxes are assessed on an annual basis and calculated by applying to an interim period's pre-tax income the tax rate that would be applicable to expected total annual earnings.

5. MATERIAL ACCOUNTING JUDGMENTS AND KEY SOURCES OF ESTIMATION UNCERTAINTY

In developing significant accounting estimates, the sources of critical accounting judgments, estimates, and assumptions used in the preparation of these consolidated financial statements are consistent with those disclosed in the 2025 consolidated financial statements. Please refer to the relevant disclosures regarding critical accounting judgments, estimates, and sources of estimation uncertainty in the 2025 consolidated financial statements.

6. CASH AND CASH EQUIVALENTS

	March 31, 2026	December 31, 2025	March 31, 2025
Cash on hand and petty cash	$ 163	$ 161	$ 156
Bank demand deposits	145,476	155,672	234,227
Cash equivalents-Time deposits with original maturities of 3 months or less	330,000	338,200	358,200
	$ 475,639	$ 494,033	$ 592,583

7. FINANCIAL INSTRUMENTS AT FAIR VALUE THROUGH PROFIT OR LOSS

	March 31, 2026	December 31, 2025	March 31, 2025
Financial assets - current			
Financial assets mandatorily classified as at FVTPL			
Non-derivative financial assets			
Domestic unlisted shares	$ -	$ -	$ -
Derivative instruments (not under hedge accounting)			
Foreign exchange forward contracts	-	70	-
	$ -	$ 70	$ -
Financial liabilities - current			
Held for trading			
Derivative instruments (not under hedge accounting)			
Foreign exchange forward contracts	$ 1,811	$ 1,234	$ 2,272

The amount of the fair value changes of financial assets designated as at FVTPL for the Three Months Ended March 31, 2026 and 2025 included the (loss) or gain on the fair value of Financial assets of $(3,531) thousand and $26 thousand, respectively, and the amount of the fair value changes of financial liabilities designated as at FVTPL for the Three Months Ended March 31, 2026 and 2025 included the loss on the fair value of financial instruments of $(2,664) thousand and $(4,725) thousand, respectively.

At the end of the reporting period, outstanding foreign exchange forward contracts not under hedge accounting were as follows:

March 31, 2026

	Currency	Maturity Date	Contract Amount (In Thousands)
Sell	USD/NTD	2026.04.07～2026.04.28	USD 8,200/NTD 260,352

December 31, 2025

	Currency	Maturity Date	Contract Amount (In Thousands)
Sell	USD/NTD	2026.01.05～2026.01.26	USD 7,500/NTD 234,414

March 31, 2025

	Currency	Maturity Date	Contract Amount (In Thousands)
Sell	USD/NTD	2025.04.07～2025.04.25	USD 7,000/NTD 229,771

The Group entered into foreign exchange forward contracts to hedge against the exchange risks on foreign currency assets and liabilities. Since these contracts did not meet the criteria for hedge accounting, the Group did not apply hedge accounting treatment for these foreign exchange forward contracts.

8. FINANCIAL ASSETS AT FAIR VALUE THROUGH OTHER COMPREHENSIVE INCOME

	March 31, 2026	December 31, 2025	March 31, 2025
Non-current			
Investments in equity instruments			
Domestic unlisted shares	$ 4,294	$ 5,550	$ 5,719

The ordinary shares of Insight Genomics Inc. and Renown Information Technology Corp. are held for medium- to long-term strategic purposes Accordingly, the management elected to designate these investments at FVTOCI as they believe that recognizing short-term fluctuations in these investments' fair value in profit or loss would not be consistent with the Group's strategy of holding these investments for long-term purposes.

The unrealized gains (losses) on the change of financial assets at FVTOCI were $(1,256) thousand and $687 thousand for the Three Months Ended March 31, 2026 and 2025, respectively.

9. ACCOUNTS RECEIVABLE AND OTHER RECEIVABLES

	March 31, 2026	December 31, 2025	March 31, 2025
Accounts receivable			
At amortized cost			
Gross carrying amount	$ 303,481	$ 286,220	$ 262,154
Less: Loss allowance	(5,189)	(8,492)	(895)
	$ 298,292	$ 277,728	$ 261,259
Other receivables			
Gross carrying amount	$ 9,744	$ 11,133	$ 6,856
Less: Loss allowance	-	-	-
	$ 9,744	$ 11,133	$ 6,856

a. Accounts receivable

The average credit period of receivables is 30 days from the end of the month to 230 days. No interest is charged on trade receivables.

In order to minimize credit risk, the management of the Company has delegated a team responsible for determining credit limits, credit approvals and other monitoring procedures to ensure that follow-up action is taken to recover overdue debts. In addition, the Group reviews the recoverable amount of each individual trade debt at the end of the reporting date to ensure that adequate allowance is made for possible irrecoverable amounts. In this regard, the management believes the Group's credit risk was significantly reduced.

The Group measures the loss allowance for trade receivables at an amount equal to lifetime ECLs. The expected credit losses on trade receivables are estimated using a provision matrix prepared by reference to the past default records of the customer, the customer's current financial position and economic condition of the industry in which the customer operates. As there are different loss patterns for various customer segments, the Group uses different provision matrixes based on historical experience, the customer's individual current financial position and the competitive advantages and prospects of the industry in which the customer operates.

The Group writes off a receivable when there is evidence indicating that the debtor is in severe financial difficulty and there is no realistic prospect of recovery. (e.g. when the debtor has been placed under liquidation). For receivables that have been written off, the Group continues to engage in enforcement activity to attempt to recover the receivables due. Where recoveries are made, these are recognized in profit or loss.

The following table details the loss allowance of accounts receivable based on the Group's provision matrix:

March 31, 2026

	Counterparties without Sign of Default					Counterparties with Sign of Default	Total
	Not Past Due	1 to 30 Days Past Due	31 to 60 Days Past Due	61 to 90 Days Past Due	Over 90 Days Past Due		
Expected credit loss rate	0%-85%	0%-4%	0%-54%	0%-54%	100%	100%	
Gross carrying amount	$ 297,001	$ 1,387	$ -	$ -	$ 4,224	$ 869	$ 303,481
Loss allowance (Lifetime ECLs)	(44)	(52)	-	-	(4,224)	(869)	(5,189)
Amortized cost	$ 296,957	$ 1,335	$ -	$ -	$ -	$ -	$ 298,292

December 31, 2025

	Counterparties without Sign of Default					Counterparties with Sign of Default	Total
	Not Past Due	1 to 30 Days Past Due	31 to 60 Days Past Due	61 to 90 Days Past Due	Over 90 Days Past Due		
Expected credit loss rate	0%-2%	0%-54%	0%-68%	0%-68%	100%	100%	
Gross carrying amount	$ 281,117	$ 3	$ -	$ -	$ 4,257	$ 843	$ 286,220
Loss allowance (Lifetime ECLs)	(3,390)	(2)	-	-	(4,257)	(843)	(8,492)
Amortized cost	$ 277,727	$ 1	$ -	$ -	$ -	$ -	$ 277,728

March 31, 2025

	Counterparties without Sign of Default					Counterparties with Sign of Default	Total
	Not Past Due	1 to 30 Days Past Due	31 to 60 Days Past Due	61 to 90 Days Past Due	Over 90 Days Past Due		
Expected credit loss rate	0%	0%	0%	0%	100%	100%	
Gross carrying amount	$ 260,815	$ 481	$ -	$ -	$ -	$ 858	$ 262,154
Loss allowance (Lifetime ECLs)	(36)	(1)	-	-	-	(858)	(895)
Amortized cost	$ 260,779	$ 480	$ -	$ -	$ -	$ -	$ 261,259

The movements of the loss allowance of accounts receivable were as follows:

	For the three months ended March 31	
	2026	2025
Balance on January 1	$ 8,492	$ 842
Add: Impairment loss recognized	-	37
Less: Impairment loss reversed	(3,328)	-
Foreign exchange gains and losses	25	16
Balance on March 31	$ 5,189	$ 895

b. Other receivables

In determining the recoverability of other receivables, the Group measures the loss allowance of other receivables according to the probability of collection of accounts, and after assessing the debtor's operating conditions and the possibility of recovery of accounts, the accounts that cannot be collected are included in the loss allowance.

10. INVENTORIES

	March 31, 2026	December 31, 2025	March 31, 2025
Finished goods	$ 94,891	$ 98,694	$ 68,500
Work in process	82,495	77,924	47,682
Raw materials	127,626	73,198	55,793
	$ 305,012	$ 249,816	$ 171,975

The cost of goods sold related to inventories for the three months ended March 31, 2026 and 2025 amounted to $160,836 thousand and $138,580 thousand, respectively. The reversals of inventory write-downs included in the cost of goods sold for the same periods were $136 thousand and $4,750 thousand, respectively.

11. SUBSIDIARIES

Subsidiaries Included in the Consolidated Financial Statements

			% of Ownership		
Investor	Investee	Main Business	March 31, 2026	December 31 2025	March 31, 2025
DIVA Laboratories, Ltd.	DIVA Laboratories U.S., LLC	Sales of monitors	100%	100%	100%
	DIVA Laboratories GmbH	Sales of monitors	100%	100%	100%
	Diva Capital Inc.	Reinvestment	100%	100%	100%
Diva Capital Inc.	Diva Holding Inc.	Reinvestment	100%	100%	100%
Diva Holding Inc.	Suzhou Diva Lab. Inc.	Medical equipment wholesale, import and export business	100%	100%	100%

12. INVESTMENTS ACCOUNTED FOR USING THE EQUITY METHOD

	March 31, 2026	December 31, 2025	March 31, 2025
Investments in associate(s)			
Associate that is not individually material			
The Linden Group Corp.	$ 2,050	$ 2,028	($ 694)
Plus: Reclassified to credit balance of using the equity method	-	-	694
	$ 2,050	$ 2,028	$ -

Associate that is not individually material

Refer to Table 2 “Information on Investees” for the nature of activities, principal place of business and country of incorporation of the associate.

On December 22, 2017, the board of directors of the Company approved a capital increase of US$1,000 thousand in The Linden Group Corp. through a cash investment, acquiring a 19% equity interest.

Although the Group owns less than 20% of The Linden Group Corp.’s shares, the Group can still exercise significant influence over The Linden Group Corp. since the transaction amount between them is material to The Linden Group Corp.

The cumulative impairment loss on the investment in The Linden Group Corp. at March 31, 2026 was $25,787 thousand.

The investments accounted for under the equity method and the share of the profit or loss and other comprehensive income for the periods from January 1 to March 31, 2026 and 2025 were recognized based on the financial statements that have not been reviewed by independent auditors.

13. PROPERTY, PLANT AND EQUIPMENT

	Freehold Land	Buildings	Transportation Equipment	Business Equipment	Mold Equipment	Others	Total
Cost							
Balance on January 1, 2026	$ 154,922	$ 85,423	$ 2,120	$ 17,215	$ 56,134	$ 21,404	$ 337,218
Additions	-	-	-	550	-	137	687
Disposals	-	-	-	-	(268)	-	(268)
Effects of foreign currency exchange differences	-	-	-	8	-	-	8
Balance on March 31, 2026	$ 154,922	$ 85,423	$ 2,120	$ 17,773	$ 55,866	$ 21,541	$ 337,645
Accumulated depreciation							
Balance on January 1, 2026	$ -	($ 35,783)	($ 972)	($ 12,555)	($ 55,023)	($ 18,351)	($ 122,684)
Depreciation expenses	-	(593)	(88)	(366)	(298)	(368)	(1,713)
Disposals	-	-	-	-	268	-	268
Effects of foreign currency exchange differences	-	-	-	(7)	-	-	(7)
Balance on March 31, 2026	$ -	($ 36,376)	($ 1,060)	($ 12,928)	($ 55,053)	($ 18,719)	($ 124,136)
Carrying amount on December 31, 2025 and January 1, 2026	$ 154,922	$ 49,640	$ 1,148	$ 4,660	$ 1,111	$ 3,053	$ 214,534
Carrying amount on March 31, 2026	$ 154,922	$ 49,047	$ 1,060	$ 4,845	$ 813	$ 2,822	$ 213,509
Cost							
Balance on January 1, 2025	$ 154,922	$ 85,423	$ 2,120	$ 31,923	$ 57,321	$ 19,375	$ 351,084
Disposals	-	-	-	(15,107)	-	(95)	(15,202)
Effects of foreign currency exchange differences	-	-	-	4	-	-	4
Balance on March 31, 2025	$ 154,922	$ 85,423	$ 2,120	$ 16,820	$ 57,321	$ 19,280	$ 335,886

(Continued)

Accumulated depreciation	Freehold Land	Buildings	Transportation Equipment	Business Equipment	Mold Equipment	Others	Total
Balance on January 1, 2025	$ -	($ 33,410)	($ 618)	($ 26,131)	($ 55,553)	($ 17,331)	($ 133,043)
Depreciation expenses	-	(593)	(88)	(385)	(351)	(360)	(1,777)
Disposals	-	-	-	15,091	-	95	15,186
Effects of foreign currency exchange differences	-	-	-	(4)	-	-	(4)
Balance on March 31, 2025	$ -	($ 34,003)	($ 706)	($ 11,429)	($ 55,904)	($ 17,596)	($ 119,638)
Carrying amount on March 31, 2025	$ 154,922	$ 51,420	$ 1,414	$ 5,391	$ 1,417	$ 1,684	$ 216,248

(Concluded)

The above items of property, plant and equipment are depreciated on a straight-line basis over the estimated useful lives as follows:

Buildings	35 years
Transportation equipment	5 years
Business equipment	2-10 years
Mold equipment	2-3 years
Others	3-5 years

14. LEASE ARRANGEMENTS

a. Right-of-use assets

	March 31, 2026	December 31, 2025	March 31, 2025
Carrying amounts			
Office equipment	$ 373	$ 397	$ 469
Buildings	1,838	2,451	4,289
	$ 2,211	$ 2,848	$ 4,758

	For the three months ended March 31	
	2026	2025
Addition to right-of-use assets	$ -	$ 477
Depreciation charge for right-of-use assets		
Office equipment	$ 24	$ 29
Buildings	613	613
	$ 637	$ 642

Except for the aforementioned right-of-use assets and related additions and recognized depreciation, there was no material sublease agreement or impairment on the Group’s right-of-use assets for the Three Months Ended March 31, 2026 and 2025.

b. Lease liabilities

	March 31, 2026	December 31, 2025	March 31, 2025
Carrying amounts			
Current	$ 1,974	$ 2,593	$ 2,554
Non-current	$ 284	$ 308	$ 2,258

Range of discount rate for lease liabilities was as follows:

	March 31, 2026	December 31, 2025	March 31, 2025
Office equipment	2.148%	2.148%	2.148%
Buildings	2.023%	2.023%	2.023%

c. Other lease information

	For the three months ended March 31	
	2026	2025
Expenses relating to short-term leases	$ 154	$ 141
Expenses relating to variable lease payments not included in the measurement of lease liabilities	$ 96	$ 45
Total cash outflow for leases	($ 760)	($ 848)

The Group has elected to apply the recognition exemption to office, warehouse and parking lot leases that qualify as short-term leases, and thus did not recognize right-of- use assets and corresponding lease liabilities in the consolidated financial statements.

All lease commitments with lease terms commencing after the balance sheet dates are as follows:

	March 31, 2026	December 31, 2025	March 31, 2025
Lease commitments	$ -	$ 129	$ -

15. INTANGIBLE ASSETS

	Computer Software
Cost	
Carrying amount on January 1 and March 31, 2026	$ 33,619
Accumulated amortization	
Balance on January 1, 2026	($ 32,623)
Amortization expenses	(174)
Balance on March 31, 2026	($ 32,797)
Carrying amount on December 31, 2025 and January 1, 2026	$ 996
Balance on March 31, 2026	$ 822
Cost	
Carrying amount on January 1 and March 31, 2025	$ 33,497

(Continued)

	Computer Software
Accumulated amortization	
Balance on January 1, 2025	($ 31,784)
Amortization expenses	(246)
Balance on March 31, 2025	($ 32,030)
Carrying amount on March 31, 2025	$ 1,467

(Concluded)

Intangible assets are amortized on a straight-line basis over their estimated useful lives as follows:

Patents	10 years
Computer software	3-5 years

An analysis of amortization expenses by functions:

	For the three months ended March 31	
	2026	2025
Operating costs	$ 126	$ 126
General and administrative expenses	38	95
Research and development expenses	10	25
	$ 174	$ 246

16. OTHER ASSETS

	March 31, 2026	December 31, 2025	March 31, 2025
Current			
Temporary payments	$ 110	$ 24	$ 227
Payment on behalf of others	6,541	4,711	3,381
	$ 6,651	$ 4,735	$ 3,608
Non-current			
Refundable deposits (Note 29)	$ 1,824	$ 1,825	$ 1,818

17. ACCOUNTS PAYABLE

	March 31, 2026	December 31, 2025	March 31, 2025
Accounts payable			
Operating	$ 92,106	$ 77,378	$ 73,194

The average credit period for purchases from domestic suppliers was 30 to 120 days from the end of the month.

18. OTHER LIABILITIES

	March 31, 2026	December 31, 2025	March 31, 2025
Current			
Other payables			
Payables for dividend	$ 117,337	$ -	$ 117,337
Payables for salaries or bonuses	17,159	31,214	16,889
Payables for processing fees	14,635	14,729	15,526
Payables for remuneration of employees and directors	11,343	9,053	12,278
Payables for annual leave	6,521	6,618	5,877
Payables for professional service fees	5,340	5,048	6,462
Payables for insurance premiums	3,417	3,085	2,834
Payables for equipment purchases	722	2,482	-
Payables for shipping fees	567	779	1,614
Payables for others	18,005	13,710	17,329
	$ 195,046	$ 86,718	$ 196,146
Other liabilities			
Temporary receipts	$ 2,471	$ 2,452	$ 2,511
Receipts under custody	9,748	14,564	9,646
	$ 12,219	$ 17,016	$ 12,157

19. PROVISIONS

	March 31, 2026	December 31, 2025	March 31, 2025
Current			
Warranties	$ 13,929	$ 13,037	$ 10,497

	Warranties
Balance on January 1, 2026	$ 13,037
Additional provisions recognized	1,126
Amount used	(234)
Balance on March 31, 2026	$ 13,929
Balance on January 1, 2025	$ 9,609
Additional provisions recognized	976
Amount used	(88)
Balance on March 31, 2025	$ 10,497

The provision for warranty claims represents the present value of management's best estimate of the future

outflow of economic benefits that will be required under the Group's obligations for warranties under contracts for the sale of goods. The estimate has been made on the basis of historical warranty trends and may vary as a result of new materials, altered manufacturing processes or other events affecting product quality.

20. RETIREMENT BENEFIT PLANS

For the Three Months Ended March 31, 2026 and 2025, the pension expenses of defined benefit plans were reduced by $13 thousand and $9 thousand, respectively, and these were calculated based on the pension cost rate determined by the actuarial calculation on December 31, 2025 and 2024, respectively.

21. EQUITY

a. Share capital

Ordinary shares

	March 31, 2026	December 31, 2025	March 31, 2025
Shares authorized (in thousands of shares)	100,000	100,000	100,000
Shares authorized (in thousands of dollars)	$ 1,000,000	$ 1,000,000	$ 1,000,000
Shares issued and fully paid (in thousands of shares)	58,668	58,668	60,091
Shares issued and fully paid (in thousands of dollars)	$ 586,682	$ 586,682	$ 600,906

The share issued had a par value of NT$10 and the right of voting and receiving dividends.

As of March 31, 2025, among the issued shares of the Company, there were 20,856 thousand privately placed common shares for which the public issuance procedures had not yet been completed. Such procedures were subsequently completed on December 12, 2025.

The amount of shares reserved from shares for granting employee share options certificates, special shares with share options and corporate bonds with share options is 5,000 thousand.

The rights and obligations of the privately placed common shares are the same as those of the Company's issued common shares. However, in accordance with the Securities and Exchange Act, except under circumstances stipulated therein, these shares may not be freely transferred prior to the completion of public issuance procedures and within three years from the date of delivery.

b. Capital surplus

Depending on the source, capital surplus arising from shares issued in excess of par value (including share premiums from the issuance of ordinary shares and the conversion of bonds payable), expired share options (employee stock options and stock options) and donated assets may be used to offset a deficit; in addition, when the Company has no deficit, this capital surplus may be distributed as cash dividends, or may be transferred to share capital once a year within a certain percentage of the Company's paid-in share capital.

c. Retained earnings and dividends policy

Under the dividends policy as set forth in the Company's Articles of Incorporation (the "Articles"), where the Company made a profit in a fiscal year, the profit shall be first utilized for paying taxes, offsetting losses of previous years, setting aside as legal capital reserve 10% of the remaining profit, until the accumulated legal capital reserve equals the Company's paid-in share capital, setting aside or reversing a special reserve in accordance with the laws and regulations, and then any remaining profit together with any undistributed retained earnings shall be used by the Company's board of directors as

the basis for proposing a distribution plan, which should be resolved in the shareholders' meeting for the distribution of dividends and bonuses to shareholders. For the policies on the distribution of compensation of employees and remuneration of directors, refer to compensation of employees and remuneration of directors in Note 23-f.

The Company's Articles also stipulate that the dividends for shareholders shall be distributed annually at not less than 10% of the distributable surplus, but no distribution may be made if the accumulated distributable surplus is less than 10% of the paid-in share capital. Dividends may be distributed in the form of both cash dividends and share dividends; however, cash dividends no be less than 30% of the total dividends distributed. If the above earnings distribution is to be made in the form of cash dividends, the board of directors is authorized to resolve and shall report to the shareholders meeting.

The Company may issue new shares or cash out of the legal reserve or capital reserve in accordance with Article 241 of the Company Act. If there will be a distribution in cash, the Board of Directors is authorized to approve this distribution and report it at the shareholder's meeting for approval.

When a special reserve is appropriated for cumulative net debit balance reserves from the prior period, the sum of net profit for the current period and items other than net profit that are included directly in the unappropriated earnings for current period is used if the prior unappropriated earnings is not sufficient.

The appropriations of earnings for 2025 and 2024, were as follows:

	Appropriation of Earnings For the Year Ended December 31	
	2025	2024
Legal reserve	$ 6,417	$ 9,412
Appropriation (Reversal of) special reserve	$ 461	($ 1,913)
Cash dividends	$ 57,294	$ 86,623
Cash dividends per share (NT$)	$ 0.97657128	$ 1.47648427

On February 26, 2025, the board of directors, in addition to approving the proposed cash dividend of NT$1.47648427 per share from unappropriated earnings, also proposed to distribute cash amounting to NT$0.52351573 per share, or a total of $30,714 thousand, from capital surplus. The Company distributed a total of NT$2 per share for the year ended December 31, 2025. The cash dividends and capital reserve distributions were approved by the board of directors on February 26, 2025, respectively. Other profit distribution items were approved at the annual general meetings held on May 27, 2025.

On February 26, 2026, the board of directors, in addition to approving the proposed cash dividend of NT$0.97657128 per share from unappropriated earnings, also proposed to distribute cash amounting to NT$1.02342872 per share, or a total of $60,043 thousand, from capital surplus. The Company is expected to distribute NT$2 per share in total for the year ending December 31, 2026. The cash dividends and capital reserve distributions were approved by the board of directors on February 26, 2026, respectively. Other profit distribution items are expected to be resolved at the annual general meetings held on May 27, 2026.

d. Special reserve

	For the three months ended March 31	
	2026	2025
Balance on January 1 and March 31	$ 5,804	$ 7,717

e. Other equity items

1) Exchange differences on translation of foreign operations

	For the three months ended March 31	
	2026	2025
Balance on January 1	$ 185	$ 1,164
Exchange differences on the translation of the net assets of foreign operations	654	506
Share of other comprehensive income of associates accounted for using the equity method	63	24
Balance on March 31	$ 902	$ 1,694

2) Unrealized valuation gain or loss on financial assets at FVTOCI

	For the three months ended March 31	
	2026	2025
Balance on January 1	($ 6,450)	($ 6,968)
Recognized for the three months		
Unrealized gain or loss		
Equity investments (Note 8)	(1,256)	687
Balance on March 31	($ 7,706)	($ 6,281)

f. Treasury shares

	Shares Transferred to Employees (In Thousands of Shares)	Carrying amount
Number of shares on March 31 and January 1, 2025	1,423	$ 45,987
Number of shares on March 31 and January 1, 2026	-	$ -

22. REVENUE

	For the three months ended March 31	
	2026	2025
Revenue from contracts with customers		
Revenue from the sale of goods	$ 222,900	$ 207,110

a. Contract balances

	March 31, 2026	December 31, 2025	March 31, 2025	January 1, 2025
Accounts receivable (Note 9)	$298,292	$277,728	$261,259	$251,214
Accounts receivable from related parties (Note 28)	$ 2,375	$ 7,771	$ 9,118	$ 11,193

(Continued)

	March 31, 2026	December 31, 2025	March 31, 2025	January 1, 2025
Contract liabilities				
Sale of goods	$ 8,388	$ 8,186	$ 6,295	$ 6,512

(Concluded)

b. Disaggregation of contract revenue

	For the three months ended March 31	
	2026	2025
Revenue recognized		
At the shipping point	$ 136,761	$ 159,302
At the point of arrival	86,139	47,808
	$ 222,900	$ 207,110

23. NET PROFIT

Net profit for this period:

a. Interest income

	For the three months ended March 31	
	2026	2025
Interest income	$ 1,230	$ 1,213

b. Other income

	For the three months ended March 31	
	2026	2025
Others (Note 28)	$ 262	$ 2,704

c. Finance cost

	For the three months ended March 31	
	2026	2025
Interest on bank loans	$ 165	$ -
Interest on lease liabilities	14	25
	$ 179	$ 25

d. Depreciation and amortization

	For the three months ended March 31	
	2026	2025
An analysis of depreciation by function		
Operating costs	$ 1,838	$ 1,832
Operating expenses	512	587
	$ 2,350	$ 2,419
An analysis of amortization by function		
Operating costs	$ 126	$ 126
Operating expenses	48	120
	$ 174	$ 246

e. Employee benefit expenses

	For the three months ended March 31	
	2026	2025
Short-term benefits	$ 43,933	$ 43,892
Post-employment benefits		
Defined contribution plan	1,511	1,480
Defined benefit plans (Note 20)	(13)	(9)
Total employee benefit expense	$ 45,431	$ 45,363
An analysis of employee benefit expense by function		
Operating costs	$ 15,946	$ 16,455
Operating expenses	29,485	28,908
	$ 45,431	$ 45,363

f. Compensation of employees and remuneration of directors

According to the Company's Articles, the Company should accrue 5% to 20% of net profit as compensation of employees and no higher than 1% as remuneration of directors. Pursuant to the amendments to the Securities and Exchange Act in August 2024, the Company intends to amend its Articles of Incorporation at the 2025 Annual General Meeting. The proposed amendment will specify that, in the event the Company reports earnings for the year, 5% to 20% of such earnings shall be allocated as employee remuneration, and no more than 1% as director remuneration. Of the total amount allocated for employee remuneration, no less than 10% shall be distributed to grassroots-level employees.

The compensation of employees and remuneration of directors for the three months ended March 31, 2026 and 2025, respectively, are as follows:

Accrual rate

	For the three months ended March 31	
	2026	2025
Compensation of employees	7.00%	7.00%
Remuneration of directors	0.75%	0.75%

Amount

	For the three months ended March 31	
	2026	2025
Compensation of employees (cash)	$ 2,069	$ 2,438
Remuneration of directors (cash)	$ 221	$ 261

If there is a subsequent change in the amounts of compensation of employees and remuneration of directors after the date the annual consolidated financial statements are authorized for issue, it will be treated as a change in accounting estimate and adjusted in the following year's accounts.

The remuneration of employees and Directors for 2025 and 2024 resolved by the Board on February 26, 2026 and February 26, 2025, respectively, are as follows:

Amount

	For the Year Ended December 31	
	2025	2024
Compensation of employees (cash)	$ 8,177	$ 8,652
Remuneration of directors (cash)	$ 876	$ 927

Information on the compensation of employees and remuneration of directors resolved by the Company's board of directors is available at the Market Observation Post System website of the Taiwan Stock Exchange.

24. INCOME TAXES

a. The major components of income tax expense recognized in profit or loss are as follows:

	For the three months ended March 31	
	2026	2025
Current tax		
In respect of the current year	$ 5,350	$ 5,837
Adjustments for prior years	(3,563)	-
Others	584	822
	2,371	6,659
Deferred tax		
In respect of the current year	106	896
Income tax expense recognized in profit or loss	$ 2,477	$ 7,555

b. Income tax assessments

The income tax returns through 2024 had been assessed by the tax authorities.

25. EARNINGS PER SHARE

	Unit: NT$ Per Share For the three months ended March 31	
	2026	**2025**
Basic earnings per share	$ 0.42	$ 0.42
Diluted earnings per share	$ 0.42	$ 0.42

The earnings and weighted average number of ordinary shares outstanding used in the computation of earnings per share were as follows:

Net income for the three months

	For the three months ended March 31	
	2026	**2025**
Net income used in the computation of basic earnings per share and diluted earnings per share	$ 24,782	$ 24,888

Weighted average number of ordinary shares outstanding

	Unit: In Thousand Shares For the three months ended March 31	
	2026	**2025**
Weighted average number of ordinary shares in the computation of basic earnings per share	58,668	58,668
Effect of potentially dilutive ordinary shares:		
Compensation of employees	214	202
Weighted average number of ordinary shares in the computation of diluted earnings per share	58,882	58,870

The Group may settle the compensation of employees in cash or shares; therefore, the Group assumes that the entire amount of the compensation will be settled in shares, and the resulting potential shares are included in the weighted average number of shares outstanding used in the computation of diluted earnings per share, as the effect is dilutive. Such dilutive effect of the potential shares is included in the computation of diluted earnings per share until the number of shares to be distributed to employees is resolved in the following year.

26. CAPITAL MANAGEMENT

The Group manages its capital to ensure that entities in the Group will be able to continue as going concerns while maximizing the return to shareholders through the optimization of the debt and equity balance.

The capital structure of the Group consists of net assets (cash and cash equivalents) and equity of the Group (comprising issued capital, reserves, retained earnings, and other equity).

The Group is not subject to any externally imposed capital requirements.

Key management personnel of the Group review the capital structure annually. As part of this review, the Group considers the cost of capital and the risks associated with each class of capital. In order to balance the overall capital structure, the Group may adjust the amount of dividends paid to shareholders, the number of new shares issued, and the amount of new debt issued or existing debt redeemed.

27. FINANCIAL INSTRUMENTS

a. Fair value of financial instruments not measured at fair value

The Group's management considers that the carrying amounts of those financial assets and financial liabilities that are not measured at fair value recognized in the consolidated financial statements approximate their fair values.

b. Fair value of financial instruments measured at fair value on a recurring basis

1) Fair value hierarchy

March 31, 2026

	Level 1	Level 2	Level 3	Total
Financial assets at FVTPL - current				
Domestic unlisted shares	$ -	$ -	$ -	$ -
Financial assets at FVTOCI - non-current				
Investments in equity instruments				
Domestic unlisted shares	$ -	$ -	$ 4,294	$ 4,294
Financial liabilities at FVTPL - current				
Derivative instruments	$ -	$ 1,811	$ -	$ 1,811

December 31, 2025

	Level 1	Level 2	Level 3	Total
Financial assets at FVTPL - current				
Domestic unlisted shares	$ -	$ -	$ -	$ -
Derivative instruments	-	70	-	70
	$ -	$ 70	$ -	$ 70
Financial assets at FVTOCI - non-current				
Investments in equity instruments				
Domestic unlisted shares	$ -	$ -	$ 5,550	$ 5,550
Financial liabilities at FVTPL - current				
Derivative instruments	$ -	$ 1,234	$ -	$ 1,234

March 31, 2025

	Level 1	Level 2	Level 3	Total
Financial assets at FVTPL - current				
Domestic unlisted shares	$ -	$ -	$ -	$ -
Financial assets at FVTOCI - non-current				
Investments in equity instruments				
Domestic unlisted shares	$ -	$ -	$ 5,719	$ 5,719
Financial liabilities at FVTPL - current				
Derivative instruments	$ -	$ 2,272	$ -	$ 2,272

The Group's financial assets measured at fair value using Level 3 inputs, and recognized other comprehensive (losses) gains of $(1,256) thousand and $687 thousand for the three months in 2026 and 2025, respectively.

There were no transfers between Levels 1 and 2 for the Three Months Ended March 31, 2026 and 2025.

2) Reconciliation of Level 3 fair value measurements of financial instruments

For the three months ended March 31, 2026

Financial Assets	Financial Assets at FVTPL: Equity Instruments	Financial Assets at FVTOCI: Equity Instruments	Total
Balance on January 1	$ -	$ 5,550	$ 5,550
Recognized in other comprehensive income or loss (unrealized profit or loss of financial assets at FVTOCI)	-	(1,256)	(1,256)
Balance on March 31	$ -	$ 4,294	$ 4,294

For the three months ended March 31, 2025

Financial Assets	Financial Assets at FVTPL: Equity Instruments	Financial Assets at FVTOCI: Equity Instruments	Total
Balance on January 1	$ -	$ 5,032	$ 5,032
Recognized in other comprehensive income or loss (unrealized profit or loss of financial assets at FVTOCI)	-	687	687
Balance on March 31	$ -	$ 5,719	$ 5,719

3) Valuation techniques and inputs applied for Level 2 fair value measurement

Financial Instruments	Valuation Technique and Inputs
Derivatives - foreign exchange forward contracts	Discounted cash flow. Future cash flows are estimated based on observable forward exchange rates at the end of the reporting date and contract forward rates, discounted at a rate that reflects the credit risk of various counterparties.

4) Valuation techniques and inputs applied for Level 3 fair value measurement

The domestic unlisted shares held by the Group and there was no market value for reference; therefore the valuation method was adopted.

c. Categories of financial instruments

	March 31, 2026	December 31, 2025	March 31, 2025
Financial assets			
FVTPL			
Mandatorily classified as at FVTPL	$ -	$ 70	$ -
Financial assets at amortized cost (1)	801,218	802,931	882,888
Financial assets at FVTOCI			
Equity instruments	4,294	5,550	5,719
Financial liabilities			
FVTPL			
Held for trading	$ 1,811	$ 1,234	$ 2,272
Amortized cost (2)	381,271	256,940	302,777

1) The balances include financial assets at amortized cost, which comprise cash and cash equivalents, accounts receivable, accounts receivable from related parties, other receivables, other receivables from related parties, and refundable deposits.

2) The balances included financial liabilities at amortized cost, which comprise accounts payable, accounts payable to related parties, other payables, and other payables to related parties.

d. Financial risk management objectives and policies

The Group's major financial instruments include debt investments, accounts receivable, and accounts payable. The Group's corporate treasury function provides services to the business, coordinates access to domestic and international financial markets, and monitors and manages the financial risks relating to the operations of the Group through internal risk reports that analyze exposures by degree and magnitude of risks. These risks include market risk (including foreign currency risk and interest rate risk), credit risk and liquidity risk.

The use of financial derivatives is governed by the Group's policies approved by the board of directors, which provided written principles on foreign currency risk, interest rate risk, credit risk, the use of financial derivatives and non-derivative financial instruments, and the investment of excess liquidity. Compliance with policies and exposure limits is reviewed by the internal auditors on a continuous basis.

The Group did not enter into or trade financial instruments, including derivative financial instruments, for speculative purposes.

1) Market risk

The Group's activities exposed it primarily to the financial risks of changes in foreign currency exchange rates (see (a) below) and interest rates (see (b) below). The Group used a variety of derivative financial instruments to manage its exposure to foreign currency risk and interest rate risk, including foreign exchange forward contracts to hedge the exchange rate risk arising on the export.

There has been no change to the Group's exposure to market risks or the manner in which these risks are managed and measured.

a) Foreign currency risk

The Group has foreign currency denominated sales and purchases, which expose the Group to foreign currency risk. Approximately 96% of the Group's sales are denominated in currencies other than the functional currency of the entity in the Group making the sale, whilst almost 57% of costs is denominated in currencies other than the functional currency of the entity in the Group. Exchange rate exposures are managed within approved policy parameters utilizing foreign exchange forward contracts.

The carrying amounts of the Group's foreign currency denominated monetary assets and monetary liabilities (including those eliminated on consolidation) and of the derivatives exposed to foreign currency risk at the end of the reporting date are set out in Note 30.

Sensitivity analysis

The Group is mainly exposed to the U.S. dollar.

The following table details the Group's sensitivity to a 1% increase and decrease in the New Taiwan dollar (i.e., the functional currency) against the relevant foreign currencies. The sensitivity rate used when reporting foreign currency risk internally to key management personnel and representing management's assessment of the reasonably possible change in foreign exchange rates is 1%. The sensitivity analysis included only outstanding foreign currency denominated monetary items and foreign exchange forward contracts, and adjusts their translation at the end of the reporting date for a 1% change in foreign currency rates. A positive number below indicates an increase in pre-tax profit associated with the New Taiwan dollar weakening 1% against the relevant currency. For a 1% strengthening of the New Taiwan dollar against the relevant currency, there would be an equal and opposite impact on pre-tax profit, and the balances below would be negative.

	Impact of USD	
	For the three months ended March 31	
	2026	2025
Profit or loss*	$ 2,741	$ 2,395

* The result was mainly attributable to the exposure on outstanding receivables and payables in U.S. dollars that were not hedged at the end of the reporting date.
The Group's increase in sensitivity to U.S. dollars during the year was mainly due to an increase in net assets denominated in U.S. dollars.

b) Interest rate risk

The risk is managed by the Group by maintaining an appropriate mix of fixed and floating rate borrowings. Hedging activities are evaluated regularly to align with interest rate views and defined risk appetites ensuring the most cost-effective hedging strategies are applied.

The carrying amounts of the Group's financial assets and financial liabilities with exposure to interest rates at the end of the reporting period were as follows:

	March 31, 2026	**December 31, 2025**	**March 31, 2025**
Fair value interest rate risk			
Financial assets	$ 330,000	$ 338,200	$ 358,200
Financial liabilities	2,258	2,901	4,812
Cash flow interest rate risk			
Financial assets	145,476	155,672	234,227

Sensitivity analysis

The sensitivity analysis below was determined based on the Group's exposure to interest rates for both derivative and non-derivative instruments at the end of the reporting date. For floating rate liabilities, the analysis was prepared assuming the amount of each liability outstanding at the end of the reporting date was outstanding for the whole year. A 1 percentage point increase or decrease is used when reporting interest rate risk internally to key management personnel and represents management's assessment of the reasonably possible change in interest rates.

If interest rates had been 1 percentage point higher/lower and all other variables were held constant, the Group's pre-tax profit for the Three Months Ended March 31, 2026 and 2025 would have decreased/increased by $364 thousand and $586 thousand, respectively.

2) Credit risk

Credit risk refers to the risk that a counterparty will default on its contractual obligations resulting in a financial loss to the Group. At the end of the reporting date, the Group's maximum exposure to credit risk, which would cause a financial loss to the Group due to the failure of the counterparty to discharge its obligation and due to the financial guarantees provided by the Group, could be equal to the total of the following:

a) The carrying amount of the respective recognized financial assets as stated in the balance sheets; and

b) The maximum amount the entity would have to pay if the financial guarantee is called upon, irrespective of the likelihood of the guarantee being exercised.

The policy adopted by the Group is to deal only with reputable parties and, where necessary, obtain sufficient collateral to mitigate the risk of financial loss arising from default. The Group will only deal with companies with a rating equivalent to the investment grade or above. This information is provided by independent rating agencies; if such information is not available, the Group will use other publicly available financial information and each other's transaction records to rate their major customers. The Group continuously monitors the exposure and the credit ratings of its counterparties, and distributes the total transaction amount to customers with sound credit ratings.

The Group transacts with a large number of unrelated customers thus, credit risk is not highly concentrated.

3) Liquidity risk

The Group manages liquidity risk by monitoring and maintaining a level of cash and cash equivalents deemed adequate to finance the Group's operations and mitigate the effects of fluctuations in cash flows. In addition, the Group's management monitors the utilization of bank borrowings and ensures compliance with loan covenants.

The Group relies on bank borrowings as a significant source of liquidity. As of March 31, 2026, December 31, 2025 and March 31, 2025, the Group had available unutilized short-term bank loan facilities set out in (c) below.

a) Liquidity and interest rate risk tables for non-derivative financial liabilities

The following table details the Group's remaining contractual maturities for its non-derivative financial liabilities with agreed upon repayment periods. The table has been drawn up based on the undiscounted cash flows of financial liabilities from the earliest date on which the Group can be required to pay. The table includes both interest and principal cash flows. Specifically, bank loans with a repayment on demand clause were included in the earliest time band regardless of the probability of the banks choosing to exercise their rights. The maturity dates for other non-derivative financial liabilities were based on the agreed upon repayment dates.

March 31, 2026

	On Demand or Less than 1 Month	1-3 Months	3 Months to 1 Year	1-5 Years	Total
Lease liabilities	$ 219	$ 438	$ 1,340	$ 293	$ 2,290

Further information on the maturity analysis of the above financial liabilities was as follows:

	Less than 1 Year	1-5 Years	5+ Years
Lease liabilities	$ 1,997	$ 293	$ -

December 31, 2025

	On Demand or Less than 1 Month	1-3 Months	3 Months to 1 Year	1-5 Years	Total
Lease liabilities	$ 219	$ 438	$ 1,972	$ 318	$ 2,947

Further information on the maturity analysis of the above financial liabilities was as follows:

	Less than 1 Year	1-5 Years	5+ Years
Lease liabilities	$ 2,629	$ 318	$ -

March 31, 2025

	On Demand or Less than 1 Month	1-3 Months	3 Months to 1 Year	1-5 Years	Total
Lease liabilities	$ 219	$ 438	$ 1,971	$ 2,290	$ 4,918

Further information on the maturity analysis of the above financial liabilities was as follows:

	Less than 1 Year	1-5 Years	5+ Years
Lease liabilities	$ 2,628	$ 2,290	$ -

b) Liquidity and interest rate risk table for derivative financial liabilities

The following table details the Group's liquidity analysis of its derivative financial instruments. The table is based on the undiscounted contractual net cash inflows and outflows on derivative instruments that settle on a net basis, and the undiscounted gross inflows and outflows on those derivatives that require gross settlement. When the amount payable or receivable is not fixed, the amount disclosed is determined by reference to the projected interest rates as illustrated by the yield curves at the end of the reporting date.

March 31, 2026

	On Demand or Less than 1 Month	1-3 Months	3 Months to 1 Year	1-5 Years	Total
Net settled					
Foreign exchange forward contracts	$ 1,811	$ -	$ -	$ -	$ 1,811

December 31, 2025

	On Demand or Less than 1 Month	1-3 Months	3 Months to 1 Year	1-5 Years	Total
Net settled					
Foreign exchange forward contracts	$ 1,234	$ -	$ -	$ -	$ 1,234

March 31, 2025

	On Demand or Less than 1 Month	1-3 Months	3 Months to 1 Year	1-5 Years	Total
Net settled					
Foreign exchange forward contracts	$ 2,272	$ -	$ -	$ -	$ 2,272

c) Financing facilities

	March 31, 2026	December 31, 2025	March 31, 2025
Unsecured bank loan facilities:			
Amount used	$ -	$ -	$ -
Amount unused	710,985	681,290	771,615
	$ 710,985	$ 681,290	$ 771,615

28. TRANSACTIONS WITH RELATED PARTIES

The Company's parent is Data Image Corporation, which held 36.26%, 36.26% and 35.40% of the ordinary shares of the Company as of March 31, 2026, December 31, 2025 and March 31, 2025, respectively. The Company's ultimate parent and ultimate controlling party is Qisda Corporation.

Balances and transactions between the Company and its subsidiaries, which are related parties of the Company, have been eliminated on consolidation and are not disclosed in this note. Besides information disclosed elsewhere in the notes, details of transactions between the Group and other related parties are disclosed as follows.

a. Related parties and their relationship with the Group

Related Party	Relationship with the Group
Qisda Corporation	Ultimate parent entity
Data Image Corporation	The Company's parent
DFI Inc.	Sister company of the parent company
Benq Asia Pacific Corp.	Sister company of the parent company
Qisda Electronics (Suzhou) Co., Ltd.	Sister company of the parent company
Concord Medical Co., Ltd.	Sister company of the parent company
Metaguru Corporation	Sister company of the parent company
BenQ Medical Technology Corporation	Sister company of the parent company
GOLDEN SPIRIT CO., LTD.	Sister company of the parent company
Simula Technology Inc.	Sister company of the parent company
ACTION STAR TECHNOLOGY CO., LTD.	Sister company of the parent company
BenQ Healthcare Corporation	Sister company of the parent company
NORBEL BABY CO.,LTD	Sister company of the parent company
BenQ Materials Corp.	Sister company of the parent company
GLOBAL INTELLIGENCE NETWORK CO., LTD.	Sister company of the parent company

(Continued)

Related Party	Relationship with the Group
Qisda Optronics (Suzhou) Co., Ltd.	Sister company of the parent company
Qisda (Suzhou) Co., Ltd.	Sister company of the parent company
DARFON ELECTRONICS CORP.	A corporate shareholder that accounts for its investment in the ultimate parent company using the equity method
Data Image (Suzhou) Corporation	Sister company
The Linden Group Corp.	Associate
Kuo-Sheng Chen	Director

(Concluded)

b. Operating revenue

Line Items	Related Party Category/Name	For the three months ended March 31 2026	2025
Sales			
	Parent entity	$ -	$ 3
	Associate		
	The Linden Group Corp.	2,337	9,092
		$ 2,337	$ 9,095

The transaction prices with related parties are determined based on the terms agreed upon by the two parties, and if there are no other similar transactions for comparison due to special specifications, the transaction prices are determined based on the sales price and credit terms agreed upon by both parties.

c. Purchases

Related Party Category	For the three months ended March 31 2026	2025
Ultimate parent entity	$ 207	$ -
A corporate shareholder that accounts for its investment in the ultimate parent company using the equity method	6	-
	$ 213	$ -

The transaction prices and credit terms of the purchase of goods by related parties shall be determined based on the purchase price and credit terms agreed upon by both parties due to special specifications and with no other similar transactions for comparison.

d. Contract liabilities

Related Party Category/Name	March 31, 2026	December 31, 2025	March 31, 2025
Associate			
The Linden Group Corp.	$ 95	$ 79	$ -

e. Receivables from related parties (excluding loans to related parties)

Line Items	Related Party Category/Name	March 31, 2026	December 31, 2025	March 31, 2025
Accounts receivable from related parties	Parent entity	$ -	$ -	$ 3
	Sister companies of the parent company	-	21	-
	Associate			
	The Linden Group Corp.	2,375	7,750	9,115
		$ 2,375	$ 7,771	$ 9,118
Other receivables from related parties	Sister companies of the parent company			
	Qisda Electronics (Suzhou) Co., Ltd.	$ 13,304	$ 10,348	$ 11,254
	Other sister companies of the parent company	40	93	-
		$ 13,344	$ 10,441	$ 11,254

The outstanding trade receivables from related parties are unsecured.

f. Payables to related parties (excluding borrowing from related parties)

Line Items	Related Party Category/Name	March 31, 2026	December 31, 2025	March 31, 2025
Accounts payable to related parties	Ultimate parent entity	$ 133	$ 89	$ -
	A corporate shareholder that accounts for its investment in the ultimate parent company using the equity method	6	1	-
		$ 139	$ 90	$ -
Other payables to related parties	Ultimate parent entity	$ 81,203	$ 80,279	$ 28,426
	Parent entity	2,517	3,422	1,993
	Sister company of the parent company			
	Qisda Electronics (Suzhou) Co., Ltd.	10,121	8,985	-
	Other sister companies of the parent company	55	32	2,974
	Associate			
	The Linden Group Corp.	84	36	44
		$ 93,980	$ 92,754	$ 33,437

The outstanding trade payables to related parties are unsecured.

g. Prepayments

Related Party Category	March 31, 2026	December 31, 2025	March 31, 2025
Sister company of the parent company	$ 101	$ 177	$ 178

The prepayment to the sister company of the parent company was for software and other services.

h. Other income

Line Items	Related Party Category/Name	For the three months ended March 31 2026	2025
Other income (Note 23)	Parent entity	$ 85	$ -
	Sister company of the parent company	113	-
	Director Kuo-Sheng Chen	-	2,120
		$ 198	$ 2,120

Labor service income was received from parent entity and sister company of the parent company; compensation income, from director of the company.

i. Lease arrangements

Related Party Category	For the three months ended March 31 2026	2025
Lease expense		
Sister company	$ 43	$ 43

The Group leased an office from its sister company. The lease term of the contract was one year and fixed lease payments are paid monthly.

Future lease payables related to short-term leases are as follows:

Related Party Category	March 31, 2026	December 31, 2025	March 31, 2025
Sister company	$ 118	$ 157	$ 116

j. Other transactions with related parties

Line Items/Name	Related Party Category	For the three months ended March 31 2026	2025
Operating cost	Ultimate parent entity	$ 4,380	$ -
	Sister company of the parent company	41	233
	Associate	64	3
		$ 4,485	$ 236
Operating cost - outsourcing fee	Ultimate parent entity	$ 2,860	$ 8,221
	Parent entity	2,360	1,876
	Sister company of the parent company	1,578	336
		$ 6,798	$ 10,433

(Continued)

Line Items/Name	Related Party Category	For the three months ended March 31 2026	2025
Operating expense	Ultimate parent entity	$ 29	$ 38
	Parent entity	-	77
	Sister company of the parent company	91	158
	Associate	17	60
		$ 137	$ 333

(Concluded)

The ultimate parent company, parent entity and associate provided inspection, testing, trial production and maintenance services to the Group.

The sister company of the parent company mainly provided miscellaneous purchases, consulting, training and software services to the Group.

k. Remuneration of key management personnel

	For the three months ended March 31 2026	2025
Short-term employee benefits	$ 4,967	$ 4,901
Post-employment benefits	54	54
	$ 5,021	$ 4,955

The remuneration of directors and key executives, as determined by the remuneration committee, is based on the performance of individuals and market trends.

29. ASSETS PLEDGED AS COLLATERAL

The following assets of the Company are pledged as collaterals for customs clearance:

	March 31, 2026	December 31, 2025	March 31, 2025
Refundable deposits	$ 500	$ 500	$ 500

30. EXCHANGE RATE OF FINANCIAL ASSETS AND LIABILITIES DENOMINATED IN FOREIGN CURRENCIES

The Group's significant financial assets and liabilities denominated in foreign currencies aggregated by the foreign currencies other than functional currencies of the entities in the Group and the related exchange rates between the foreign currencies and the respective functional currencies were as follows:

March 31, 2026

	Foreign Currency	Exchange Rate	Carrying Amount
Financial assets			
Monetary items			
USD	$ 11,503	31.995	$ 368,036
Financial liabilities			
Monetary items			
USD	2,935	31.995	93,918

December 31, 2025

	Foreign Currency	Exchange Rate	Carrying Amount
Financial assets			
Monetary items			
USD	$ 10,687	31.43	$ 335,902
Financial liabilities			
Monetary items			
USD	3,168	31.43	99,563

March 31, 2025

	Foreign Currency	Exchange Rate	Carrying Amount
Financial assets			
Monetary items			
USD	$ 9,532	33.205	$ 316,519
Financial liabilities			
Monetary items			
USD	2,320	33.205	77,046

For the Three Months Ended March 31, 2026 and 2025, realized and unrealized foreign exchange (losses) gains were net exchange gains of $4,838 thousand and $3,401 thousand.

31. SEPARATELY DISCLOSED ITEMS

a. Information on significant transactions:

1) Financing provided to others: None

2) Endorsements/guarantees provided: None

3) Marketable securities held: None

4) Total purchases from or sales to related parties amounting to at least NT$100 million or 20% of the paid-in capital: None

5) Receivables from related parties amounting to at least NT$100 million or 20% of the paid-in capital: None

6) Intercompany relationships and significant intercompany transactions (Table 1)

b. Information on investees (Table 2)

c. Information on investments in mainland China

1) Information on any investee company in mainland China, showing the name, principal business activities, paid-in capital, method of investment, inward and outward remittance of funds, ownership percentage, net income of investees, investment income or loss, carrying amount of the investment at the end of the reporting date, repatriations of investment income, and limit on the amount of investment in the mainland China area (Table 3)

2) Any of the following significant transactions with investee companies in mainland China, either directly or indirectly through a third party, and their prices, payment terms, and unrealized gains or losses: None

a) The amount and percentage of purchases and the balance and percentage of the related payables at the end of the reporting date

b) The amount and percentage of sales and the balance and percentage of the related receivables at the end of the reporting date

c) The amount of property transactions and the amount of the resultant gains or losses

d) The balance of negotiable instrument endorsements or guarantees or pledges of collateral at the end of the reporting date and the purposes

e) The highest balance, the ending balance, the interest rate range, and total current period interest with respect to the financing of funds

f) Other transactions that have a material effect on the profit or loss for the year or on the financial position, such as the rendering or receipt of services

32. SEGMENT INFORMATION

Information reported to the chief operating decision maker for the purpose of resource allocation and assessment of segment performance focuses on the types of goods or services delivered or provided.

The medical monitors segment includes a number of direct sales operations in various cities within China and Taiwan, each of which is considered a separate operating segment by the chief operating decision

maker (CODM). For the purposes of financial statement presentation, these individual operating segments have been aggregated into a single operating segment, taking into account the following factors:

1) The nature of the products and production processes are similar.

2) The methods used to distribute the products to the customers are the same.

a. Consolidated revenues and results

The following is an analysis of the Group's revenue and results from operations by reportable segments:

For the three months ended March 31, 2026

	Business Department Taiwan	Business Department Overseas	Total
Revenue from external customers	$ 215,045	$ 7,855	$ 222,900
Inter-segment revenue	229	-	229
Segment revenue	215,274	7,855	223,129
Eliminations	(229)	-	(229)
Consolidated revenue	$ 215,045	$ 7,855	222,900
Segment income	$ 30,518	($ 2,994)	27,524
Interest income			1,230
Other income			262
Other gains or losses			(1,357)
Compensation of directors			(221)
Finance cost			(179)
Profit before tax			$ 27,259

For the three months ended March 31, 2025

	Business Department Taiwan	Business Department Overseas	Total
Revenue from external customers	$ 201,896	$ 5,214	$ 207,110
Inter-segment revenue	2,947	-	2,947
Segment revenue	204,843	5,214	210,057
Eliminations	(2,947)	-	(2,947)
Consolidated revenue	$ 201,896	$ 5,214	207,110
Segment income	$ 33,471	($ 3,339)	30,132
Interest income			1,213
Other income			2,704
Other gains or losses			(1,314)
Compensation of directors			(261)
Finance cost			(25)
The profit or loss of associate recognized under equity method			(6)
Profit before tax			$ 32,443

Inter-segment revenue was accounted for according to market prices.

Segment profit represents the profit before tax earned by each segment without allocation of central

administration costs and directors' salaries, share of profit of associates, interest income, gain or loss on disposal of property, plant and equipment, exchange gains or (losses), valuation gains on financial instruments, finance cost and income tax expense. This was the measure reported to the chief operating decision maker for the purpose of resource allocation and assessment of segment performance.

b. Total segment assets and liabilities

	March 31, 2026	December 31, 2025	March 31, 2025
Segment assets			
Business department - Taiwan	$ 1,319,853	$ 1,292,975	$ 1,274,305
Business department - Overseas	22,538	19,592	18,933
Unallocated assets	41,082	41,113	40,906
Consolidated total assets	$ 1,383,473	$ 1,353,680	$ 1,334,144
Segment liabilities			
Business department - Taiwan	($ 408,648)	($ 290,346)	($ 332,983)
Business department - Overseas	(11,228)	(8,968)	(5,827)
Unallocated liabilities	(27,528)	(25,203)	(31,064)
Consolidated total liabilities	($ 447,404)	($ 324,517)	($ 369,874)

For the purpose of monitoring segment performance and allocating resources between segments:

1) All assets were allocated to reportable segments, other than investments accounted for using the equity method and current and deferred tax assets. Assets used jointly by reportable segments were allocated based on the revenue earned by individual reportable segments; and

2) All liabilities were allocated to reportable segments other than Credit balance of investments accounted for using the equity method, current and deferred tax liabilities. Liabilities for which reportable segments are jointly liable were allocated in proportion to segment assets.

DIVA LABORATORIES, LTD. AND SUBSIDIARIES

INTERCOMPANY RELATIONSHIPS AND SIGNIFICANT INTERCOMPANY TRANSACTIONS
For the three months ended March 31, 2026
(In Thousands of New Taiwan Dollars)

No.	Investee Company (Note 1)	Counterparty	Transaction Flow (Note 2)	Transaction Details			
				Financial Statement Account	Amount (Note 3)	Payment Terms	% of Total Sales or Assets
0	DIVA Laboratories, Ltd.	DIVA Laboratories U.S., LLC Suzhou Diva Lab. Inc.	1 1	Other payables to related parties Sales revenue	($ 19,952) (5,456)	Net 75 days Note 4	1% 2%
1	DIVA Laboratories U.S., LLC	DIVA Laboratories, Ltd.	2	Other receivables from related parties	19,952	Net 75 days	1%
2	Suzhou Diva Lab. Inc.	DIVA Laboratories, Ltd.	2	Purchase	5,456	Note 4	2%

Note 1: The No. column is denoted as follows:

1. Parent is numbered 0.
2. Subsidiaries are sequentially numbered starting from 1.

Note 2: Transaction flow:

1. From parent to subsidiary.
2. From subsidiary to parent.
3. Between subsidiaries.

Note 3: At the time of preparation of the consolidated financial statements, it was fully written off.

Note 4: The trading price is comparable to those in the market.

Note 5: The disclosure standard is that the amount of major intercompany transactions should reach more than 1% of the consolidated revenue or total assets.

DIVA LABORATORIES, LTD. AND SUBSIDIARIES

INFORMATION ON INVESTEES
For the three months ended March 31, 2026
(In Thousands of New Taiwan Dollars, Unless Stated Otherwise)

Investor Company	Investee Company	Location	Main Businesses and Products	Original Investment Amount		As of March 31, 2026			Net Income (Loss) of the Investee	Share of Profit (Loss)	Note
				March 31, 2026	December 31, 2025	Number of Shares	Ratio (%)	Carrying Amount			
DIVA Laboratories, Ltd	DIVA Laboratories GmbH	Germany	Sales of monitors	$ 25,092 (EUR 664 thousand)	$ 25,092 (EUR 664 thousand)	-	100	$ 814	($ 34) (EUR 1 thousand)	($ 34) (EUR 1 thousand)	Note 5
	DIVA Laboratories U.S., LLC	U.S.	Sales of monitors	35,858 (US$ 1,150 thousand)	35,858 (US$ 1,150 thousand)	-	100	19,748	(1,919) (US$ 61 thousand)	(1,919) (US$ 61 thousand)	Note 5
	Diva Capital Inc.	Samoa	Reinvestment	52,908 (US$ 1,745 thousand)	52,908 (US$ 1,745 thousand)	-	100	10,197	396 (US$ 13 thousand)	396 (US$ 13 thousand)	Notes 1 and 5
	The Linden Group Corp.	U.S.	Sales of monitors	30,015 (US$ 1,000 thousand)	30,015 (US$ 1,000 thousand)	-	19	2,050	-	-	Notes 2 and 3
Diva Capital Inc.	Diva Holding Inc.	Samoa	Reinvestment	52,598 (US$ 1,735 thousand)	52,598 (US$ 1,735 thousand)	-	100	10,314	396 (US$ 13 thousand)	Note 4	Note 5

Note 1: The carrying amount deducted the unrealized gain on downstream transactions of $119 thousand.

Note 2: The carrying amount deducted the unrealized gain on downstream transactions of $1,507 thousand.

Note 3: The Company recognized the cumulative impairment loss of $25,787 thousand on its investment accounted for using the equity method in The Linden Group Corp.

Note 4: The profit and loss of the investee company has been included in its investor company. To avoid confusion, it will not be expressed separately.

Note 5: The profit and loss of reinvested inter-company investments, investment accounted for using the equity method and the net assets of the investee companies have been fully written off when preparing the consolidated financial statements.

DIVA LABORATORIES, LTD. AND SUBSIDIARIES

INFORMATION ON INVESTMENTS IN MAINLAND CHINA
For the three months ended March 31, 2026
(In Thousands of New Taiwan Dollars, Unless Stated Otherwise)

Investee Company	Main Businesses and Products	Paid-in Capital	Method of Investment	Accumulated Outward Remittance for Investment from Taiwan at the Beginning of Period	Remittance of Funds		Accumulated Outward Remittance for Investment from Taiwan at the End of Period	Net Gain (Loss) of the Investee	% Ownership of Direct or Indirect Investment	Investment Gain (Loss)	Carrying amount on the End of Period	Accumulated Repatriation of Investment Income at the End of Period	Note
					Outward	Inward							
Suzhou Diva Lab. Inc.	Medical equipment wholesale, import and export business	$ 52,643 (US$ 1,725 thousand)	Diva Capital Inc., a 100% owned third region subsidiary, reinvested in a third region company Diva Holding Inc., and reinvested in a mainland China company	$ 52,643 (US$ 1,725 thousand)	$ -	$ -	$ 52,643 (US$ 1,725 thousand)	$ 396 (RMB 88 thousand)	100%	$ 396 (RMB 88 thousand)	$ 10,284 (RMB 2,220 thousand)	$ -	

Accumulated Outward Remittance for Investment in Mainland China as of March 31, 2026	Investment Amounts Authorized by Investment Commission, MOEA	Upper Limit on the Amount of Investments Stipulated by the Investment Commission, MOEA (Note 1)
$52,643	US$2,000 thousand (Note 2)	$ 936,069×60%＝$ 561,641

Note 1: It is calculated according to the limit of consolidated net value based on the provisions of the relevant directives and orders of the Investment Commission under the Ministry of Economic Affairs.

Note 2: As of March 31, 2026, the Company had remitted an accumulated investment amount of US$1,725 thousand from Taiwan and an unexecuted investment amount of US$275 thousand.

Note 3: The gain or loss on inter-company investments, the long-term equity investment of the investment company and the net equity value of the investee company have been fully written off at the time of preparing the consolidated financial statements.